TIPARP and prostate carcinoma: It negatively regulates tank binding kinase 1 activity, which restrains phosphorylation and activation of the transcription factor IRF3,[19] inhibiting androgen‐induced ADP‐ribosylation of the androgen receptor in prostate cancer[34] and trapping PARP7 within the nucleus.